$TCRT
Alaunos Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000095017021001446 Filed on August 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $398.0K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.173M $9.069M $6.560M
YoY Change 28.71% 38.25% 37.82%
% of Gross Profit
Research & Development $14.52M $13.57M $12.05M
YoY Change 3.96% 12.6% 20.53%
% of Gross Profit
Depreciation & Amortization $673.0K $679.0K $250.0K
YoY Change -4.94% 171.6% 56.25%
% of Gross Profit
Operating Expenses $22.69M $22.64M $18.61M
YoY Change 11.68% 21.68% 26.12%
Operating Profit -$22.30M -$22.64M -$18.61M
YoY Change 9.72% 21.68% 26.12%
Interest Expense -$444.0K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$437.0K -$31.00K $10.00K
YoY Change -7383.33% -410.0% -92.48%
Pretax Income -$22.73M -$22.67M -$18.60M
YoY Change 11.88% 21.88% 27.22%
Income Tax
% Of Pretax Income
Net Earnings -$22.73M -$22.67M -$18.60M
YoY Change 11.9% 21.91% 27.2%
Net Earnings / Revenue -5711.81%
Basic Earnings Per Share -$0.11 -$0.11
Diluted Earnings Per Share -$106.0K -$0.11 -$0.09
COMMON SHARES
Basic Shares Outstanding 215.6M 214.4M
Diluted Shares Outstanding 214.5M 214.4M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $91.73M $76.75M $153.5M
YoY Change -32.29% -50.0% 252.06%
Cash & Equivalents $91.70M $76.70M $153.5M
Short-Term Investments
Other Short-Term Assets $3.319M $5.035M $15.60M
YoY Change -76.58% -67.72% -25.0%
Inventory
Prepaid Expenses
Receivables $1.510M $7.626M $4.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $96.55M $89.41M $173.2M
YoY Change -37.74% -48.38% 162.99%
LONG-TERM ASSETS
Property, Plant & Equipment $11.66M $11.61M $7.600M
YoY Change 17.24% 52.71% 766.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000K $16.00K $900.0K
YoY Change -99.77% -98.22% -81.52%
Total Long-Term Assets $17.21M $17.36M $8.500M
YoY Change 58.99% 104.21% 16.22%
TOTAL ASSETS
Total Short-Term Assets $96.55M $89.41M $173.2M
Total Long-Term Assets $17.21M $17.36M $8.500M
Total Assets $113.8M $106.8M $181.7M
YoY Change -31.42% -41.24% 148.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.463M $982.0K $1.100M
YoY Change -44.14% -10.73% 16.9%
Accrued Expenses $13.96M $11.85M $16.00M
YoY Change -16.4% -25.96% 81.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.04M
YoY Change
Total Short-Term Liabilities $28.17M $13.59M $17.10M
YoY Change 45.82% -20.51% 64.42%
LONG-TERM LIABILITIES
Long-Term Debt $12.17M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.708M $4.891M $1.200M
YoY Change 184.47% 307.58% 50.0%
Total Long-Term Liabilities $12.17M $4.891M $1.200M
YoY Change 635.59% 307.58% 50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.17M $13.59M $17.10M
Total Long-Term Liabilities $12.17M $4.891M $1.200M
Total Liabilities $45.06M $18.48M $18.30M
YoY Change 114.79% 1.01% 63.71%
SHAREHOLDERS EQUITY
Retained Earnings -$831.1M -$808.3M
YoY Change
Common Stock $899.8M $896.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.71M $88.28M $163.4M
YoY Change
Total Liabilities & Shareholders Equity $113.8M $106.8M $181.7M
YoY Change -31.42% -41.24% 148.32%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$22.73M -$22.67M -$18.60M
YoY Change 11.9% 21.91% 27.2%
Depreciation, Depletion And Amortization $673.0K $679.0K $250.0K
YoY Change -4.94% 171.6% 56.25%
Cash From Operating Activities -$9.577M -$21.45M -$14.00M
YoY Change -76.04% 53.23% 73.05%
INVESTING ACTIVITIES
Capital Expenditures -$370.0K -$1.877M $3.490M
YoY Change -93.85% -153.78% 4885.71%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$370.0K -$1.877M -$3.490M
YoY Change -93.85% -46.22% 4885.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.93M 19.00K 10.00K
YoY Change -75.5% 90.0% -95.65%
NET CHANGE
Cash From Operating Activities -9.577M -21.45M -14.00M
Cash From Investing Activities -370.0K -1.877M -3.490M
Cash From Financing Activities 24.93M 19.00K 10.00K
Net Change In Cash 14.98M -23.31M -17.48M
YoY Change -73.12% 33.35% 120.43%
FREE CASH FLOW
Cash From Operating Activities -$9.577M -$21.45M -$14.00M
Capital Expenditures -$370.0K -$1.877M $3.490M
Free Cash Flow -$9.207M -$19.58M -$17.49M
YoY Change -72.89% 11.92% 114.34%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
215559148
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM Oncology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
One First Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Parris Building 34, Navy Yard Plaza
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
259-1970
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
ZIOP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76746000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
115069000
CY2021Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
7626000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5035000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10855000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
89407000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
130589000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11606000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
4665000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3995000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10231000
CY2021Q2 us-gaap Liabilities
Liabilities
18484000
CY2020Q4 us-gaap Liabilities
Liabilities
22363000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4650000
CY2021Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
365000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
745000
CY2021Q2 us-gaap Assets
Assets
106765000
CY2020Q4 us-gaap Assets
Assets
146345000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
982000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
960000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11846000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16589000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
765000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
819000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13593000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18368000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4891000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
215559148
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
215559148
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
214591906
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
214591906
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
216000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
215000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
896390000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
887868000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-808325000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-764101000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
106765000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146345000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13570000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12051000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26906000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24757000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9069000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6555000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17296000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12509000
ziop Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
843000
ziop Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-361000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
22639000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
18606000
us-gaap Operating Expenses
OperatingExpenses
44202000
us-gaap Operating Expenses
OperatingExpenses
37266000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22639000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18606000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44202000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37266000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-31000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
377000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22670000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18596000
us-gaap Net Income Loss
NetIncomeLoss
-44224000
us-gaap Net Income Loss
NetIncomeLoss
-36889000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214426406
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
212792403
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
214191839
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
206303586
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
105641000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5290000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-22670000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7486000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1036000
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
0
us-gaap Net Income Loss
NetIncomeLoss
-44224000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
180337000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1661000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18596000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
163414000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
95010000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3601000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
ziop Stock Issued During Period Issuance Of Common Stock In Connection With Public Offering
StockIssuedDuringPeriodIssuanceOfCommonStockInConnectionWithPublicOffering
88661000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
13015000
us-gaap Net Income Loss
NetIncomeLoss
-36889000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
163414000
us-gaap Net Income Loss
NetIncomeLoss
-44224000
us-gaap Net Income Loss
NetIncomeLoss
-36889000
us-gaap Depreciation
Depreciation
1219000
us-gaap Depreciation
Depreciation
390000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
7486000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
3601000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2961000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
742000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5820000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6838000
ziop Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
721000
ziop Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-389000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-493000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
634000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
176000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4742000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3320000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36765000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23912000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2594000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2594000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1036000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
0
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
88661000
ziop Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
0
ziop Net Proceeds From At The Market Stock Offering
NetProceedsFromAtTheMarketStockOffering
13015000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1036000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101692000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38323000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
73780000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79741000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76746000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
153521000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
258000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1026000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76700000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-808300000
us-gaap Line Of Credit Facility Frequency Of Payment And Payment Terms
LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
The term loan amortization date is April 1, 2022; provided, however, if the Company raises $50M in funding on or prior to March 31, 2022, the term loan first payment date shall automatically be extended to September 1, 2022. Further, if the Company raised $50M on or prior to March 31, 2022 and an additional $50M on or prior to August 31, 2022, the term loan amortization shall automatically be extended to September 1, 2023. The term loan maturity date is March 1, 2023; provided, however, if Company achieves the funding milestones, the term loan maturity date shall automatically be extended to August 1, 2025. There is a final payment due of 5.75%.
CY2021Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
5000
CY2020Q4 ziop Minimum Royalties Amount Payable
MinimumRoyaltiesAmountPayable
100000
CY2020Q4 ziop Expected Cash Payment Payable
ExpectedCashPaymentPayable
1500000
CY2019Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1038
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q2 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
10000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33988064
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
31051879
CY2021Q2 ziop Payment For Annual License Fees
PaymentForAnnualLicenseFees
0
CY2017 ziop License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2019Q1 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
2000
CY2021Q2 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
9800
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
380000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
236000
us-gaap Operating Lease Cost
OperatingLeaseCost
761000
us-gaap Operating Lease Cost
OperatingLeaseCost
471000
CY2021Q2 us-gaap Lease Cost
LeaseCost
380000
CY2020Q2 us-gaap Lease Cost
LeaseCost
236000
us-gaap Lease Cost
LeaseCost
761000
us-gaap Lease Cost
LeaseCost
471000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M9D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M9D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
10417
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
347267
CY2021Q2 ziop Additional Stock Compensation Expenses
AdditionalStockCompensationExpenses
1900000
ziop Additional Stock Compensation Expenses
AdditionalStockCompensationExpenses
2000000.0
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
617000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1102000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1132000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1166000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1201000
CY2021Q2 ziop Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1873000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7091000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1435000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5656000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5290000
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1661000
us-gaap Share Based Compensation
ShareBasedCompensation
7486000
us-gaap Share Based Compensation
ShareBasedCompensation
3601000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
41500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4395438
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.44
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
153000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1049000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.55
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
216700
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
751371
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7292
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0043
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0060
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0009
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0168
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7408
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7310
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7390
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7480
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7111
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7374
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6840719
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4395438
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.79
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
363109
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
686219
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.86
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10186829
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
899000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4970314
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M23D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
771000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3596315
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
598000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1427152
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000

Files In Submission

Name View Source Status
0000950170-21-001446-index-headers.html Edgar Link pending
0000950170-21-001446-index.html Edgar Link pending
0000950170-21-001446.txt Edgar Link pending
0000950170-21-001446-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20210630.htm Edgar Link pending
ziop-20210630.xsd Edgar Link pending
ziop-20210630ex31_1.htm Edgar Link pending
ziop-20210630ex31_2.htm Edgar Link pending
ziop-20210630ex32_1.htm Edgar Link pending
ziop-20210630_cal.xml Edgar Link unprocessable
ziop-20210630_def.xml Edgar Link unprocessable
ziop-20210630_htm.xml Edgar Link completed
ziop-20210630_lab.xml Edgar Link unprocessable
ziop-20210630_pre.xml Edgar Link unprocessable